ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Author(s) -
Ingo K. Mellinghoff,
Mehdi Touat,
Elizabeth A. Maher,
Macarena DeLaFuente,
Timothy F. Cloughesy,
Matthias Holdhoff,
Gregory M. Coté,
Howard Burris,
Filip Jankú,
Raymond Y. Huang,
Robert R. Young,
Benjamin M. Ellingson,
Julia Auer,
Hua Liu,
Jonathan Hurov,
Katherine Yen,
Sam Agresta,
Eyal C. Attar,
Susan Pandya,
Patrick Y. Wen
Publication year - 2016
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/now212.044
Subject(s) - glioma , isocitrate dehydrogenase , idh1 , medicine , fluid attenuated inversion recovery , oncology , cancer research , mutant , biology , radiology , magnetic resonance imaging , gene , enzyme , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom